85 related articles for article (PubMed ID: 23859252)
1. Immunotoxicity and genotoxicity testing of PLGA-PEO nanoparticles in human blood cell model.
Tulinska J; Kazimirova A; Kuricova M; Barancokova M; Liskova A; Neubauerova E; Drlickova M; Ciampor F; Vavra I; Bilanicova D; Pojana G; Staruchova M; Horvathova M; Jahnova E; Volkovova K; Bartusova M; Cagalinec M; Dusinska M
Nanotoxicology; 2015 May; 9 Suppl 1():33-43. PubMed ID: 23859252
[TBL] [Abstract][Full Text] [Related]
2. Genotoxicity testing of PLGA-PEO nanoparticles in TK6 cells by the comet assay and the cytokinesis-block micronucleus assay.
Kazimirova A; Magdolenova Z; Barancokova M; Staruchova M; Volkovova K; Dusinska M
Mutat Res; 2012 Oct; 748(1-2):42-7. PubMed ID: 22814198
[TBL] [Abstract][Full Text] [Related]
3. Influence of the surface charge of PLGA nanoparticles on their in vitro genotoxicity, cytotoxicity, ROS production and endocytosis.
Platel A; Carpentier R; Becart E; Mordacq G; Betbeder D; Nesslany F
J Appl Toxicol; 2016 Mar; 36(3):434-44. PubMed ID: 26487569
[TBL] [Abstract][Full Text] [Related]
4. Hydrophobic sodium fluoride-based nanocrystals doped with lanthanide ions: assessment of in vitro toxicity to human blood lymphocytes and phagocytes.
Sojka B; Kuricova M; Liskova A; Bartusova M; Banski M; Misiewicz J; Dusinska M; Horvathova M; Jahnova E; Ilavska S; Szabova M; Rollerova E; Podhorodecki A; Tulinska J
J Appl Toxicol; 2014 Nov; 34(11):1220-5. PubMed ID: 25179008
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells.
Grabowski N; Hillaireau H; Vergnaud J; Santiago LA; Kerdine-Romer S; Pallardy M; Tsapis N; Fattal E
Int J Pharm; 2013 Oct; 454(2):686-94. PubMed ID: 23747506
[TBL] [Abstract][Full Text] [Related]
6. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
[TBL] [Abstract][Full Text] [Related]
7. Surface coating mediates the toxicity of polymeric nanoparticles towards human-like macrophages.
Grabowski N; Hillaireau H; Vergnaud J; Tsapis N; Pallardy M; Kerdine-Römer S; Fattal E
Int J Pharm; 2015 Mar; 482(1-2):75-83. PubMed ID: 25448553
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxicity of poly (lactic-co-glycolic acid) nanoparticles: influence of surface properties on dendritic cell activation.
Barillet S; Fattal E; Mura S; Tsapis N; Pallardy M; Hillaireau H; Kerdine-Römer S
Nanotoxicology; 2019 Jun; 13(5):606-622. PubMed ID: 30760076
[TBL] [Abstract][Full Text] [Related]
9. Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures.
Chronopoulou L; Massimi M; Giardi MF; Cametti C; Devirgiliis LC; Dentini M; Palocci C
Colloids Surf B Biointerfaces; 2013 Mar; 103():310-7. PubMed ID: 23261553
[TBL] [Abstract][Full Text] [Related]
10. Toxicity evaluation of monodisperse PEGylated magnetic nanoparticles for nanomedicine.
Patsula V; Tulinska J; Trachtová Š; Kuricova M; Liskova A; Španová A; Ciampor F; Vavra I; Rittich B; Ursinyova M; Dusinska M; Ilavska S; Horvathova M; Masanova V; Uhnakova I; Horák D
Nanotoxicology; 2019 May; 13(4):510-526. PubMed ID: 30704361
[TBL] [Abstract][Full Text] [Related]
11. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
12. Size dependency of PLGA-nanoparticle uptake and antifungal activity against Aspergillus flavus.
Patel NR; Damann K; Leonardi C; Sabliov CM
Nanomedicine (Lond); 2011 Oct; 6(8):1381-95. PubMed ID: 21651442
[TBL] [Abstract][Full Text] [Related]
13. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells.
Han R; Zhu J; Yang X; Xu H
J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162
[TBL] [Abstract][Full Text] [Related]
14. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
[TBL] [Abstract][Full Text] [Related]
15. Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release.
Chhabra R; Grabrucker AM; Veratti P; Belletti D; Boeckers TM; Vandelli MA; Forni F; Tosi G; Ruozi B
Int J Pharm; 2014 Aug; 471(1-2):349-57. PubMed ID: 24882034
[TBL] [Abstract][Full Text] [Related]
16. Multiple cytotoxic and genotoxic effects induced in vitro by differently shaped copper oxide nanomaterials.
Di Bucchianico S; Fabbrizi MR; Misra SK; Valsami-Jones E; Berhanu D; Reip P; Bergamaschi E; Migliore L
Mutagenesis; 2013 May; 28(3):287-99. PubMed ID: 23462852
[TBL] [Abstract][Full Text] [Related]
17. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
[TBL] [Abstract][Full Text] [Related]
18. Effects of surfactants on the properties of PLGA nanoparticles.
Menon JU; Kona S; Wadajkar AS; Desai F; Vadla A; Nguyen KT
J Biomed Mater Res A; 2012 Aug; 100(8):1998-2005. PubMed ID: 22566409
[TBL] [Abstract][Full Text] [Related]
19. Size influences the cytotoxicity of poly (lactic-co-glycolic acid) (PLGA) and titanium dioxide (TiO(2)) nanoparticles.
Xiong S; George S; Yu H; Damoiseaux R; France B; Ng KW; Loo JS
Arch Toxicol; 2013 Jun; 87(6):1075-86. PubMed ID: 22983807
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.
Kirby BP; Pabari R; Chen CN; Al Baharna M; Walsh J; Ramtoola Z
J Pharm Pharmacol; 2013 Oct; 65(10):1473-81. PubMed ID: 24028614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
